Rethinking the Philippines' E-Cigarette Law: Manila Standard Editorial

Feb.07.2024
Rethinking the Philippines' E-Cigarette Law: Manila Standard Editorial
Philippine newspaper Manila Standard calls for a reassessment of the country's e-cigarette law in an editorial.

The large Philippine newspaper Manila Standard recently published an editorial calling for a reassessment of the country's e-cigarette bill.


On July 25, 2022, the Republic Act No. 11900 was enacted in the Philippines with the aim of regulating the importation, sale, packaging, distribution, use, and promotion of "vaporized nicotine and non-nicotine products, as well as new tobacco products such as vape and heated tobacco products." However, in the past two years since its introduction, the law has lowered the age restriction for such products from 21 to 18 years old, lifted the ban on smoking and using heated tobacco products in public places, and allowed advertising and promotion of these products.


The law allows for the online sale of products with nicotine concentrations not exceeding 65 milligrams per milliliter (6.5%), and lowers the legal purchasing age from 21 to 18. This means that more young people will be able to use e-cigarettes as an alternative to smoking (the legal age to purchase cigarettes is 18).


The editorial argues that this law overlooks the fact that tobacco is the highest risk factor for causing deaths and disabilities in both smokers and non-smokers in 2019.


It is estimated that tobacco use was responsible for over 112,112 deaths, accounting for 27% of the total deaths in the Philippines that year.


According to researchers, 96,000 deaths (85%) are caused by smoking, while 22,000 deaths (19%) are caused by secondhand smoke. It is estimated that approximately 8 million people die prematurely every year due to cigarette smoke, which is a complex mixture of chemicals combined with aerosol particles or present in the gas phase. This has been a major health issue for several decades.


The report also noted that the main reasons why students use e-cigarettes include easy online access (32%), flavors (22%), and a perception that e-cigarettes are safer than traditional cigarettes (17%).


Editorial: The editorial asserts that e-cigarettes have not been around for a long time, and authorities are still uncertain about the long-term risks associated with their use. While the harm posed by vaping is considerably lesser than smoking, it cannot be deemed entirely harmless. This is where the problem lies. Therefore, the healthiest choice would be to abstain from smoking or vaping altogether.


The editorial also quotes health experts saying, "If someone uses e-cigarettes to quit smoking, their ultimate goal should be to eventually quit using e-cigarettes." The article further mentions that according to research, emerging data suggests a link between e-cigarettes and chronic lung diseases and asthma. Additionally, using both e-cigarettes and traditional cigarettes has also been associated with cardiovascular diseases.


In conclusion, there is not much difference between smoking and using e-cigarettes, as stated in the editorial. People generally believe that smoking is more harmful because the products are burned and smoke is inhaled into the lungs. However, research has shown that the damage caused by heating and inhaling solution vapor into the lungs is very similar to that of smoke. Based on this, the report calls for a reevaluation of the country's e-cigarette legislation.


The Manila Standard newspaper was established on February 11, 1987. It is controlled by the Romualdez political family, specifically the current Speaker of the House of Representatives, Ferdinand Martin Gomez Romualdez.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore Seeks to Toss CCELL Price-Fixing Claim as Court Weighs Vertical Distribution Versus Horizontal Conspiracy
Smoore and four authorized U.S. CCELL distributors are asking a California federal court to permanently dismiss a core antitrust claim brought by direct purchasers. Plaintiffs allege that Smoore coordinated minimum wholesale prices, customer allocation and limits on price competition among distributors, amounting to a per se unlawful horizontal conspiracy. The defendants say the alleged conduct reflects ordinary vertical relationships between a manufacturer and its distributors. The court previously dismissed a similar claim, and the latest dispute centers on whether the second amended complaint adds sufficient facts to establish a horizontal agreement.
Sep.14
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Reynolds Seeks to Join Altria Lawsuit Challenging FDA PMTA Rule and Calculation of 180-Day Deadline
Three R.J. Reynolds companies are seeking to intervene in a lawsuit filed by Altria subsidiaries Helix Innovations and NJOY challenging the FDA's 2021 PMTA final rule. The companies dispute how the agency uses Acceptance and Filing reviews and completeness determinations to establish when the Tobacco Control Act's 180-day decision period begins. Reynolds has also linked prolonged PMTA reviews to competition from unauthorized vaping products. The FDA, meanwhile, has been accelerating reviews and reducing its backlog.
Sep.14
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Inside Nicotine-Pouch M&A Through Imperial's Yoik Deal: Latham, KPMG, PwC, Goldman Sachs and Morgan Stanley Form the Adviser Lineup
Imperial Brands' acquisition of Swedish Helwit owner Yoik Group AB has highlighted the professional-services firms supporting cross-border oral nicotine M&A. Latham & Watkins and KPMG advised Imperial, while PwC and TM & Partners advised Yoik. KPMG also appeared on Imperial's acquisition of Black Buffalo earlier in 2026, while PwC played an extensive role in KT&G's acquisition of Swedish nicotine-pouch company Another Snus Factory. Imperial's public disclosures put the global modern oral nicotine delivery market at approximately £8.8 billion in retail sales and 23.5 billion pouches in 2024
Sep.20
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Pennsylvania began enforcing its electronic nicotine delivery system directory restrictions on October 19, 2026. Among 163 product listings recorded before enforcement, four CrossBar 20K disposables stood out with 13mL capacity, advertised puff counts of up to 20,000 and a flattened design distinct from conventional pod systems and compact disposables. Historical records identify earlier 1.3mL CrossBar products associated with Romo LLC, while newer 13mL products appeared in several state directories beginning in 2025 under entities including Blue Nine LLC. PMTA compliance expert Mr. K identified amendments and application ownership transfers as possible regulatory mechanisms, although neither has been confirmed in this case. Separately, Reynolds' $7.5 million acquisition of 16 PACHA products and related assets illustrates the commercial value of products linked to historic PMTA submissions.
Special Report
Oct.22
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
Special Report | From New York to Washington: How FDA’s Tobacco Center Is Reworking Product Review
FDA’s Center for Tobacco Products is reshaping how it approaches tobacco product review. Based on 2Firsts’ on-site reporting in New York and Washington, this report traces CTP’s emerging direction: stronger links between PMTA and tobacco harm reduction, more category-specific review, greater emphasis on decision-relevant science, more predictable timelines and expanded use of sPMTA for product modifications. CTP also acknowledged major constraints, including just nine PMTA review teams, persistent backlogs and limits on hiring capacity.
Regulations
Oct.08